Experience in management of porphyria cutanea tarda in a tertiary referral Brazilian hospital from 2002 to 2017

Imagem de Miniatura
Arquivos
art_ARTEAGA_Experience_in_management_of_porphyria_cutanea_tarda_in_2019.PDF (412.79 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
INTERNATIONAL JOURNAL OF DERMATOLOGY, v.58, n.8, p.925-932, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Porphyria cutanea tarda (PCT) is the most common porphyria worldwide. The known acquired precipitating factors that induce PCT include alcoholism, hepatitis C virus infection, human immunodeficiency virus infection, and estrogen intake. Hereditary hemochromatosis is considered an inherited risk factor. The aim of this study was to describe and analyze precipitating factors and family history, with emphasis on PCT management. Methods A retrospective study of 87 patients with PCT was conducted between January 2002 and December 2017. Results A male predominance of 1.8 : 1 was found. The median age at diagnosis was 49 years (range 18-71). Family history of PCT was observed in 19.5% of patients. Two or more acquired precipitating factors were present in 42.5%. Patients were treated with antimalarial monotherapy (72.4%), antimalarial combined with phlebotomy (22.9%), and only with phlebotomy (4.6%). Acquired precipitating factors and inherited factors were not associated with treatment group. There was a difference in 24 h-UP normalization rate between treatment groups; combined therapy takes longer than antimalarial monotherapy, 38 months versus 15 months, respectively (CI 95%, 6.5-63.5 vs. 12.9-17) (log-rank test, P = 0.004). Conclusion Precipitating factors did not seem to be associated with treatment choice; however, all acquired and inherited precipitating factors should be investigated, and the choice between phlebotomy and/or antimalarials should be individualized. All dermatologists treating PCT patients should observe transferrin saturation and ferritin levels to search for underlying hereditary hemochromatosis.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/33069
Referências
  1. Aarsand AK, 2009, CLIN CHEM, V55, P795, DOI 10.1373/clinchem.2008.117432
  2. Ajioka RS, 2008, BLOOD, V112, P4723, DOI 10.1182/blood-2008-02-138222
  3. Bacon BR, 2001, GASTROENTEROLOGY, V120, P718, DOI 10.1053/gast.2001.21913
  4. Bernardes F, 2012, REV SOC BRAS MED TRO, V45, P764, DOI 10.1590/S0037-86822012000600022
  5. Bickers DR, 2012, FITZPATRICKS DERMATO, P1228
  6. Browning DJ, 2014, HYDROXYCHLOROQUINE C, P65
  7. Bulaj ZJ, 2000, BLOOD, V95, P1565
  8. Bygum A, 2003, ACTA DERM-VENEREOL, V83, P115, DOI 10.1080/00015550310007454
  9. CAINELLI T, 1983, BRIT J DERMATOL, V108, P593, DOI 10.1111/j.1365-2133.1983.tb01062.x
  10. Cançado Rodolfo D., 2007, Rev. Bras. Hematol. Hemoter., V29, P351, DOI 10.1590/S1516-84842007000400007
  11. CHINARRO S, 1983, BIOCHEM INT, V6, P565
  12. Combalia A, 2017, BRIT J DERMATOL, V177, pE183, DOI 10.1111/bjd.15502
  13. DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z
  14. DIPADOVA C, 1983, AM J MED SCI, V285, P2, DOI 10.1097/00000441-198301000-00001
  15. Dorr PG, 2016, HEMATOL TRANSFUS INT, V2, P1
  16. Egger NG, 2002, DIGEST DIS SCI, V47, P419, DOI 10.1023/A:1013746828074
  17. Egger NG, 1996, CHEM-BIOL INTERACT, V102, P69, DOI 10.1016/S0009-2797(96)03732-5
  18. ELDER GH, 1989, CLIN BIOCHEM, V22, P163, DOI 10.1016/S0009-9120(89)80072-4
  19. GOERZ G, 1985, ARCH DERMATOL RES, V277, P114, DOI 10.1007/BF00414107
  20. Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
  21. GROSSMAN ME, 1979, AM J MED, V67, P277, DOI 10.1016/0002-9343(79)90403-0
  22. Handler NS, 2017, INT J DERMATOL, V56, pe106, DOI 10.1111/ijd.13580
  23. Horner ME, 2013, INT J DERMATOL, V52, P1464, DOI 10.1111/ijd.12305
  24. Huang YC, 2013, QJM-INT J MED, V106, P591, DOI 10.1093/qjmed/hcs115
  25. Jalil S, 2010, CLIN GASTROENTEROL H, V8, P297, DOI 10.1016/j.cgh.2009.11.017
  26. Vieira FMJ, 2013, AN BRAS DERMATOL, V88, P530, DOI 10.1590/abd1806-4841.20132048
  27. Kim KH, 2016, J BLOOD MED, V7, P139, DOI 10.2147/JBM.S108479
  28. Kordac V, 1981, Cas Lek Cesk, V120, P1225
  29. Kostler E, 2005, EXPERT OPIN PHARMACO, V6, P377, DOI 10.1517/14656566.6.3.377
  30. Kostler E, 1990, Z Hautkr, V65, P1030
  31. KOTAL P, 1984, INT J BIOCHEM, V16, P1087, DOI 10.1016/0020-711X(84)90093-4
  32. Mansourati FF, 1999, INT J STD AIDS, V10, P51, DOI 10.1258/0956462991912944
  33. Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
  34. Mehrany K, 2004, J AM ACAD DERMATOL, V51, P205, DOI 10.1016/j.jaad.2003.08.015
  35. Mendez M, 2005, J AM ACAD DERMATOL, V52, P417, DOI 10.1016/j.jaad.2004.09.014
  36. Phillips JD, 2008, BLOOD, V112, P3454
  37. Pietrangelo A, 2010, J HEPATOL, V53, P3, DOI 10.1016/j.jhep.2010.03.001
  38. Poh-Fitzpatrick MB, 2012, CLIN GASTROENTEROL H, V10, P1410, DOI 10.1016/j.cgh.2012.09.005
  39. Rossmann-Ringdahl I, 2005, ACTA DERM-VENEREOL, V85, P337, DOI 10.1080/00015550510033688
  40. Ryan C F, 2012, LIVER INT, V32, P880, DOI 10.1111/J.1478-3231.2012.02794.X
  41. SALTZER EI, 1968, ARCH DERMATOL, V98, P496, DOI 10.1001/archderm.98.5.496
  42. Singal AK, 2012, CLIN GASTROENTEROL H, V10, P1402, DOI 10.1016/j.cgh.2012.08.038
  43. Stolzel U, 2003, ARCH DERMATOL, V139, P309, DOI 10.1001/archderm.139.3.309
  44. TALJAARD JJ, 1972, BRIT J DERMATOL, V87, P261, DOI 10.1111/j.1365-2133.1972.tb00316.x
  45. Toll A, 2006, ACTA DERM-VENEREOL, V86, P279, DOI 10.2340/00015555-0061
  46. Waalen J, 2002, MAYO CLIN PROC, V77, P522, DOI 10.4065/77.6.522
  47. World Health Organization, 2014, WORLD HLTH ORG GLOB

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03